LQDA — Liquidia Corporation

Liquidia Corporation (LQDA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $148.3 million for the full year 2025, with $90.1 million in Q4, representing a 74% increase over Q3 2025.
• Profitability: Achieved non-GAAP adjusted EBITDA of $27.3 million and net income of $14.6 million in Q4.
• Cash Position: Ended 2025 with approximately $190.7 million in cash and cash equivalents, generating $33 million in positive cash flow in Q4.
• Market Share: Increased from 10% to 17% of the inhaled treprostinil market revenue in Q4, indicating strong growth and market capture.

2. Strategic Updates and Business Highlights

• Product Launch: Eutrebia has been recognized as one of the top specialty drug launches in recent years, with over 3,600 unique patient referrals and therapy shipped to over 2,900 patients since launch.
• Patient Demographics: 75% of new patients are naive to prostacyclins, with 25% transitioning from other therapies, primarily inhaled options.
• Clinical Studies: Plans to initiate multiple new studies to explore further applications of Eutrebia, including transitioning patients from other prostacyclin therapies and expanding into new disease areas.
• Sales Force Expansion: Aiming to increase the sales force by one-third to enhance market penetration, particularly in the PHILD space.

3. Forward Guidance and Outlook

• Revenue Target: Confident in achieving at least $1 billion in revenue by 2027, supported by continued patient growth and market share expansion.
• Market Dynamics: The company expects sustained growth in both PAH and PHILD indications, with ongoing studies to solidify Eutrebia's position as a best-in-class therapy.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Concerns regarding new entrants in the oral prostacyclin market and the potential impact of a competitor's soft mist inhaler (SMI) on Eutrebia's launch trajectory. However, management remains confident that Eutrebia's tolerability and efficacy will mitigate these risks.
• Legal Uncertainty: Ongoing legal proceedings with no new updates, which may affect future operations and market positioning.
• Payer Access: While achieving an 85% patient start conversion, there are ongoing efforts to improve access with additional payers needed to come online.

5. Notable Q&A Insights

• Market Share Discussion: Management indicated that they are capturing a disproportionate share of new patient starts, with a focus on transitioning patients from oral therapies to Eutrebia.
• Competitive Landscape: The company downplayed the potential impact of new oral therapies, asserting that Eutrebia's profile offers superior tolerability and efficacy.
• Patient Transition Dynamics: Approximately 30% of transitioning patients in PAH are moving from oral prostacyclins, with a growing interest in Eutrebia among healthcare providers.
• Future Studies: Plans for exploratory trials to support label enhancements and transition strategies from existing therapies to Eutrebia, particularly in systemic sclerosis-associated Raynaud's phenomenon.

Overall, Liquidia Corporation demonstrated strong financial performance and strategic momentum in 2025, with a positive outlook for continued growth despite competitive challenges and legal uncertainties.